Endogenous Follistatin-Like 1 Guarantees the Immunomodulatory Properties of Mesenchymal Stem Cells during Liver Fibrotic Therapy

Investigators characterized the potential role of follistatin-like 1 in MSC-based anti-fibrotic therapy and further elucidated the mechanisms underlying its action.